Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/or calcium (RECORD trial)

Alison Avenell; Graeme S. Maclennan; David J. Jenkinson; Gladys C. McPherson; Alison M. McDonald; Puspa R. Pant; Adrian M. Grant; Marion K. Campbell; Frazer H. Anderson; Cyrus Cooper; Roger M. Francis; William J. Gillespie; C. Michael Robinson; David J. Torgerson; W Angus. Wallace; the RECORD Trial Group

doi:10.1210/jc.2011-1309

Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D₃ and/or calcium (RECORD trial)

Alison Avenell, Graeme S. Maclennan, David J. Jenkinson, Gladys C. McPherson, Alison M. McDonald, Puspa R. Pant, Adrian M. Grant, Marion K. Campbell, Frazer H. Anderson, Cyrus Cooper, Roger M. Francis, William J. Gillespie, C. Michael Robinson, David J. Torgerson, W Angus. Wallace, the RECORD Trial Group

Research output: Contribution to journal › Article › peer-review

173 Citations (Scopus)

6 Downloads (Pure)

Abstract

Context: Vitamin D or calcium supplementation may have effects on vascular disease and cancer.

Objective: Our objective was to investigate whether vitamin D or calcium supplementation affects mortality, vascular disease, and cancer in older people.

Design and Setting: The study included long-term follow-up of participants in a two by two factorial, randomized controlled trial from 21 orthopedic centers in the United Kingdom.

Participants: Participants were 5292 people (85% women) aged at least 70 yr with previous low-trauma fracture.

Interventions: Participants were randomly allocated to daily vitamin D3 (800 IU), calcium (1000 mg), both, or placebo for 24–62 months, with a follow-up of 3 yr after intervention.

Main Outcome Measures: All-cause mortality, vascular disease mortality, cancer mortality, and cancer incidence were evaluated.

Results: In intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95% confidence interval (CI) = 0.85–1.02], vascular disease mortality (HR = 0.91; 95% CI = 0.79–1.05), cancer mortality (HR = 0.85; 95% CI = 0.68–1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92–1.25) did not differ significantly between participants allocated vitamin D and those not. All-cause mortality (HR = 1.03; 95% CI = 0.94–1.13), vascular disease mortality (HR = 1.07; 95% CI = 0.92–1.24), cancer mortality (HR = 1.13; 95% CI = 0.91–1.40), and cancer incidence (HR = 1.06; 95% CI = 0.91–1.23) also did not differ significantly between participants allocated calcium and those not. In a post hoc statistical analysis adjusting for compliance, thus with fewer participants, trends for reduced mortality with vitamin D and increased mortality with calcium were accentuated, although all results remain nonsignificant.

Conclusions: Daily vitamin D or calcium supplementation did not affect mortality, vascular disease, cancer mortality, or cancer incidence.

Original language	English
Pages (from-to)	614-622
Number of pages	9
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	97
Issue number	2
Early online date	23 Nov 2011
DOIs	https://doi.org/10.1210/jc.2011-1309
Publication status	Published - 1 Feb 2012

Access to Document

10.1210/jc.2011-1309

Avenell 2011Final published version, 139 KB

Fingerprint Dive into the research topics of 'Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D<sub>3</sub> and/or calcium (RECORD trial)'. Together they form a unique fingerprint.

Cite this

Avenell, A., Maclennan, G. S., Jenkinson, D. J., McPherson, G. C., McDonald, A. M., Pant, P. R., Grant, A. M., Campbell, M. K., Anderson, F. H., Cooper, C., Francis, R. M., Gillespie, W. J., Robinson, C. M., Torgerson, D. J., Wallace, W. A., & the RECORD Trial Group (2012). Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D₃ and/or calcium (RECORD trial). Journal of Clinical Endocrinology and Metabolism, 97(2), 614-622. https://doi.org/10.1210/jc.2011-1309

Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D₃ and/or calcium (RECORD trial). / Avenell, Alison ; Maclennan, Graeme S.; Jenkinson, David J.; McPherson, Gladys C.; McDonald, Alison M.; Pant, Puspa R.; Grant, Adrian M.; Campbell, Marion K.; Anderson, Frazer H.; Cooper, Cyrus; Francis, Roger M.; Gillespie, William J.; Robinson, C. Michael; Torgerson, David J.; Wallace, W Angus.; the RECORD Trial Group.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 97, No. 2, 01.02.2012, p. 614-622.

Research output: Contribution to journal › Article › peer-review

Avenell, A , Maclennan, GS, Jenkinson, DJ, McPherson, GC, McDonald, AM, Pant, PR, Grant, AM, Campbell, MK, Anderson, FH, Cooper, C, Francis, RM, Gillespie, WJ, Robinson, CM, Torgerson, DJ, Wallace, WA & the RECORD Trial Group 2012, 'Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D₃ and/or calcium (RECORD trial)', Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 2, pp. 614-622. https://doi.org/10.1210/jc.2011-1309

Avenell, Alison ; Maclennan, Graeme S. ; Jenkinson, David J. ; McPherson, Gladys C. ; McDonald, Alison M. ; Pant, Puspa R. ; Grant, Adrian M. ; Campbell, Marion K. ; Anderson, Frazer H. ; Cooper, Cyrus ; Francis, Roger M. ; Gillespie, William J. ; Robinson, C. Michael ; Torgerson, David J. ; Wallace, W Angus. ; the RECORD Trial Group. / Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D₃ and/or calcium (RECORD trial). In: Journal of Clinical Endocrinology and Metabolism. 2012 ; Vol. 97, No. 2. pp. 614-622.

@article{91b75f45e9b241f080ed5d49cf5fb4e8,

title = "Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/or calcium (RECORD trial)",

abstract = "Context: Vitamin D or calcium supplementation may have effects on vascular disease and cancer.Objective: Our objective was to investigate whether vitamin D or calcium supplementation affects mortality, vascular disease, and cancer in older people.Design and Setting: The study included long-term follow-up of participants in a two by two factorial, randomized controlled trial from 21 orthopedic centers in the United Kingdom.Participants: Participants were 5292 people (85% women) aged at least 70 yr with previous low-trauma fracture.Interventions: Participants were randomly allocated to daily vitamin D3 (800 IU), calcium (1000 mg), both, or placebo for 24–62 months, with a follow-up of 3 yr after intervention.Main Outcome Measures: All-cause mortality, vascular disease mortality, cancer mortality, and cancer incidence were evaluated.Results: In intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95% confidence interval (CI) = 0.85–1.02], vascular disease mortality (HR = 0.91; 95% CI = 0.79–1.05), cancer mortality (HR = 0.85; 95% CI = 0.68–1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92–1.25) did not differ significantly between participants allocated vitamin D and those not. All-cause mortality (HR = 1.03; 95% CI = 0.94–1.13), vascular disease mortality (HR = 1.07; 95% CI = 0.92–1.24), cancer mortality (HR = 1.13; 95% CI = 0.91–1.40), and cancer incidence (HR = 1.06; 95% CI = 0.91–1.23) also did not differ significantly between participants allocated calcium and those not. In a post hoc statistical analysis adjusting for compliance, thus with fewer participants, trends for reduced mortality with vitamin D and increased mortality with calcium were accentuated, although all results remain nonsignificant.Conclusions: Daily vitamin D or calcium supplementation did not affect mortality, vascular disease, cancer mortality, or cancer incidence.",

author = "Alison Avenell and Maclennan, {Graeme S.} and Jenkinson, {David J.} and McPherson, {Gladys C.} and McDonald, {Alison M.} and Pant, {Puspa R.} and Grant, {Adrian M.} and Campbell, {Marion K.} and Anderson, {Frazer H.} and Cyrus Cooper and Francis, {Roger M.} and Gillespie, {William J.} and Robinson, {C. Michael} and Torgerson, {David J.} and Wallace, {W Angus.} and {the RECORD Trial Group}",

year = "2012",

month = feb,

day = "1",

doi = "10.1210/jc.2011-1309",

language = "English",

volume = "97",

pages = "614--622",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "The Endocrine Society",

number = "2",

}

TY - JOUR

T1 - Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/or calcium (RECORD trial)

AU - Avenell, Alison

AU - Maclennan, Graeme S.

AU - Jenkinson, David J.

AU - McPherson, Gladys C.

AU - McDonald, Alison M.

AU - Pant, Puspa R.

AU - Grant, Adrian M.

AU - Campbell, Marion K.

AU - Anderson, Frazer H.

AU - Cooper, Cyrus

AU - Francis, Roger M.

AU - Gillespie, William J.

AU - Robinson, C. Michael

AU - Torgerson, David J.

AU - Wallace, W Angus.

AU - the RECORD Trial Group

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Context: Vitamin D or calcium supplementation may have effects on vascular disease and cancer.Objective: Our objective was to investigate whether vitamin D or calcium supplementation affects mortality, vascular disease, and cancer in older people.Design and Setting: The study included long-term follow-up of participants in a two by two factorial, randomized controlled trial from 21 orthopedic centers in the United Kingdom.Participants: Participants were 5292 people (85% women) aged at least 70 yr with previous low-trauma fracture.Interventions: Participants were randomly allocated to daily vitamin D3 (800 IU), calcium (1000 mg), both, or placebo for 24–62 months, with a follow-up of 3 yr after intervention.Main Outcome Measures: All-cause mortality, vascular disease mortality, cancer mortality, and cancer incidence were evaluated.Results: In intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95% confidence interval (CI) = 0.85–1.02], vascular disease mortality (HR = 0.91; 95% CI = 0.79–1.05), cancer mortality (HR = 0.85; 95% CI = 0.68–1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92–1.25) did not differ significantly between participants allocated vitamin D and those not. All-cause mortality (HR = 1.03; 95% CI = 0.94–1.13), vascular disease mortality (HR = 1.07; 95% CI = 0.92–1.24), cancer mortality (HR = 1.13; 95% CI = 0.91–1.40), and cancer incidence (HR = 1.06; 95% CI = 0.91–1.23) also did not differ significantly between participants allocated calcium and those not. In a post hoc statistical analysis adjusting for compliance, thus with fewer participants, trends for reduced mortality with vitamin D and increased mortality with calcium were accentuated, although all results remain nonsignificant.Conclusions: Daily vitamin D or calcium supplementation did not affect mortality, vascular disease, cancer mortality, or cancer incidence.

AB - Context: Vitamin D or calcium supplementation may have effects on vascular disease and cancer.Objective: Our objective was to investigate whether vitamin D or calcium supplementation affects mortality, vascular disease, and cancer in older people.Design and Setting: The study included long-term follow-up of participants in a two by two factorial, randomized controlled trial from 21 orthopedic centers in the United Kingdom.Participants: Participants were 5292 people (85% women) aged at least 70 yr with previous low-trauma fracture.Interventions: Participants were randomly allocated to daily vitamin D3 (800 IU), calcium (1000 mg), both, or placebo for 24–62 months, with a follow-up of 3 yr after intervention.Main Outcome Measures: All-cause mortality, vascular disease mortality, cancer mortality, and cancer incidence were evaluated.Results: In intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95% confidence interval (CI) = 0.85–1.02], vascular disease mortality (HR = 0.91; 95% CI = 0.79–1.05), cancer mortality (HR = 0.85; 95% CI = 0.68–1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92–1.25) did not differ significantly between participants allocated vitamin D and those not. All-cause mortality (HR = 1.03; 95% CI = 0.94–1.13), vascular disease mortality (HR = 1.07; 95% CI = 0.92–1.24), cancer mortality (HR = 1.13; 95% CI = 0.91–1.40), and cancer incidence (HR = 1.06; 95% CI = 0.91–1.23) also did not differ significantly between participants allocated calcium and those not. In a post hoc statistical analysis adjusting for compliance, thus with fewer participants, trends for reduced mortality with vitamin D and increased mortality with calcium were accentuated, although all results remain nonsignificant.Conclusions: Daily vitamin D or calcium supplementation did not affect mortality, vascular disease, cancer mortality, or cancer incidence.

U2 - 10.1210/jc.2011-1309

DO - 10.1210/jc.2011-1309

M3 - Article

C2 - 22112804

VL - 97

SP - 614

EP - 622

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -